Sunovion drug could help treat binge eating
Courtesy
Sunovion's headquarters in Marlborough.
Marlborough drugmaker Sunovion Pharmaceuticals, citing results of a study, said an investigatory drug to treat binge eating disorder has yielded positive results.
Sunovion didn’t provide specific numbers, but said the drug, dasotraline, demonstrated statistically significant improvement at the 12-week primary end point of the study.
The company said the drug was generally well-tolerated in doses of 4 milligrams and 6 milligrams, with relatively mild side effects of insomnia, dry mouth, headache, decreased appetite, nausea and anxiety.
The drug was originally developed to treat attention deficit hyperactivity disorder and binge eating. The company last August submitted a new drug application to the U.S. Food and Drug Administration for the drug to treat ADHD. A decision on FDA approval is expected later this year.
The company will release the full results of its two studies on dasotraline for binge eating treatment later this fiscal year in preparation for market applications.
WBJ Web Partners
Most Recent
Most Recent
0 Comments